Join our daily newsletter At The Bell to receive exclusive market insights
- The REMAP-CAP Data Safety Monitoring Board (DSMB) has recommended Dimerix (DXB) continues enrolments for its ACE2 renin angiotensin system (RAS) modulation study
- Dimerix has so far recruited 662 COVID-19 pneumonia patients in Europe with 485 of those recruited in sites across the UK
- The DMX-200 drug aims to prevent the damaging immune response and lung flooding and DXB says it may benefit patients with a range of respiratory diseases as well as the COVID variants
- The company said should current recruitment rates continue, the study is expected to be fully enrolled by the end of the first quarter of 2022
- Dimerix shares have been trading steady at 23.5 cents each
Dimerix (DXB) has recruited 662 patients with COVID-19 pneumonia into its ACE2 renin angiotensin system (RAS) modulation study, which is trialling the DMX-200 product.
Of the 662 patients in Europe, 485 were recruited in sites across the UK and represents a 39 per cent increase in just over three weeks.
The study is sponsored by REMAP-CAP (Randomised, Embedded, Multi-factorial, Adaptive Platform Trial for Community-Acquired Pneumonia), an organisation dedicated to evaluating interventions for treating CAP.
The REMAP-CAP Data Safety Monitoring Board (DSMB) has completed an evaluation of the available study data for patient safety, conduct and progress and its recommendation is to continue enrolling within the ACE2 RAS domain and the study overall.
According to the World Health Organisation, COVID-19 deaths between November 29 and December 5 increased by 10 per cent globally, with the African region reporting the largest increase and Europe reporting the highest incidence of COVID-19.
DMX-200 is a lead drug candidate which is being developed and trialled for focal segmental glomerulosclerosis (FSGS), respiratory complications associated with COVID-19 and diabetic kidney disease.
DMX-200 aims to prevent the damaging immune response and lung flooding regardless of vaccination or antiviral treatment. As such, Dimerix said the drug may be beneficial for patients with a range of respiratory diseases in addition to the COVID variants.
The drug has regulatory and ethics approval in the UK and the Netherlands and is available for administration to patients randomised to the DMX-200 treatment arm. The company also expects approvals for additional sites across Europe, including Italy and France, over the coming months.
The company said should current recruitment rates continue, the study is expected to be fully enrolled by the end of the first quarter of 2022. Preliminary data would be available soon after.
Dimerix shares were trading steady at 23.5 cents each at 1:36 pm AEDT.
